- Home
- SLGL vs ELEV Comparison
SLGL vs ELEV Comparison
Compare SLGL & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- ELEV
- Stock Information
- Founded
- SLGL 1997
- ELEV 2019
- Country
- SLGL Israel
- ELEV United States
- Employees
- SLGL N/A
- ELEV N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- ELEV Health Care
- Exchange
- SLGL Nasdaq
- ELEV Nasdaq
- Market Cap
- SLGL 19.3M
- ELEV 22.6M
- IPO Year
- SLGL 2018
- ELEV 2021
- Fundamental
- Price
- SLGL $11.00
- ELEV $0.37
- Analyst Decision
- SLGL Buy
- ELEV Hold
- Analyst Count
- SLGL 1
- ELEV 6
- Target Price
- SLGL $40.00
- ELEV $1.77
- AVG Volume (30 Days)
- SLGL 10.1K
- ELEV 1.2M
- Earning Date
- SLGL 08-15-2025
- ELEV 08-05-2025
- Dividend Yield
- SLGL N/A
- ELEV N/A
- EPS Growth
- SLGL N/A
- ELEV N/A
- EPS
- SLGL N/A
- ELEV N/A
- Revenue
- SLGL $12,103,000.00
- ELEV N/A
- Revenue This Year
- SLGL N/A
- ELEV N/A
- Revenue Next Year
- SLGL $31.17
- ELEV N/A
- P/E Ratio
- SLGL N/A
- ELEV N/A
- Revenue Growth
- SLGL 603.66
- ELEV N/A
- 52 Week Low
- SLGL $3.34
- ELEV $0.22
- 52 Week High
- SLGL $16.50
- ELEV $3.09
- Technical
- Relative Strength Index (RSI)
- SLGL 80.53
- ELEV 45.79
- Support Level
- SLGL $9.17
- ELEV $0.35
- Resistance Level
- SLGL $8.49
- ELEV $0.38
- Average True Range (ATR)
- SLGL 0.68
- ELEV 0.01
- MACD
- SLGL 0.33
- ELEV -0.00
- Stochastic Oscillator
- SLGL 97.35
- ELEV 34.34
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.